- | AltruBio
AltruBio snags a CMO after pivot from oncology to immunology
AltruBio has signed a new chief medical officer, five months after a makeover that saw it change its name, its focus and its board.
- | Cardiff Oncology
Cardiff reveals early data on challenger to Amgen’s KRAS crown
Cardiff’s onvansertib is being trialed in a phase 1b/2 study in patients with metastatic colorectal cancer who have a mutation of the KRAS gene, according to a Wednesday release. The therapy is being combined with chemotherapy and Roche’s stalwart Avastin. Patients must have failed on chemotherapy and or/Avastin prior to entry in the trial.
- | IMV Inc.
The Search Intensifies for Cancer Treatments with Fewer Side Effects
Dorigo is principal investigator of a clinical trial of a new immunotherapy called maveropepimut-S. It’s being developed by IMV Inc., a pharmaceutical company focused on innovative immune cell activating approaches.
- | Araris Biotech
New ADC Linker Tech Shows Efficacy, Safety Advantages
At the heart of Araris’ platform is its proprietary line of indication-specific peptide linkers with finely tuned hydrophilicity to accommodate various payloads, composed from an enzyme that’s already been approved by the FDA for food use. A native glycosylated antibody, the Araris linker with the payload, bind to form the ADC under the catalyzing effect of the enzyme.
- | ProQR
Eli Lilly bets on an RNA base editing outfit leveraging the body’s own enzymes to reverse mutations
With its controversial Alzheimer’s med donanemab nearly ready for FDA scrutiny, Eli Lilly has grown more emboldened in its efforts to become the top dog in neuroscience. A new partnership with a quiet RNA editing player focused around neuroscience could now add even more bite to Lilly’s bark.
- | SOTIO
CTO Shares Secrets To A Successful Cell & Gene Therapy Supply Chain Strategy
“It’s not exactly rocket science,” Ludek Sojka, CTO, SOTIO, admitted during our conversation on managing raw material supplier relationships to better control overall C&G therapy COGS. However, the past year has proven that securing a reliable supply of raw materials will — despite our best intentions — always be an evergreen challenge. A great reminder of this came in the form of a survey earlier this year revealing that dual-source supply chains — though they are regularly heralded as essential — still remain mythical for 50 percent of advanced therapy survey respondents.
- | Fountain Therapeutics
Fountain’s William Greene is Striving to Extend Human Health Span
What it means to age is changing, and William Greene, M.D., CEO of Fountain Therapeutics, is one of those driving the change. Rather than focusing primarily on lifespan, he and his company are focusing on healthspan, and in particular, the impact of chronic degenerative diseases. The goal is to restore cellular resilience.
- | DURECT
Episode 21-37 One-way streets in Pompeii ???
On this week’s Tech Nation, from the bumpy history of the chariot to how smartphones are essential equipment for transportation in the future. Economist deputy editor Tom Standage talks about “A Brief History of Motion: From the Wheel, to the Car, to What Comes Next”. Then Dr. Jim Brown, the CEO of DURECT, describes their first Phase 2 clinical trials for Alcoholic Hepatitis, known as AH. And a look at what comes next for their approach to regenerative medicine.
